Abstract: The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. Moreover, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are also proposed for facilitating the person skilled in Lactobacillus filed capable of carrying out the strain identification of the NTU 101 according to the present invention. Moreover, the person skilled in Lactobacillus filed can also rapidly complete the strain identification of the NTU 101 by using DNA molecular marker technology, without culturing any isolated Lactobacillus strain or live Lactobacillus bacteria.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. Moreover, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are also proposed for facilitating the person skilled in Lactobacillus filed capable of carrying out the strain identification of the NTU 101 according to the present invention. Moreover, the person skilled in Lactobacillus filed can also rapidly complete the strain identification of the NTU 101 by using DNA molecular marker technology, without culturing any isolated Lactobacillus strain or live Lactobacillus bacteria.

Abstract: The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Abstract: The invention provides a composition comprising a mixture of extracts obtained from Atractylodes macrocephala, Astragalus membranaceus, Taraxacum mongolicum, Poria cocos, Ligusticum chuanxiong, Ligustrum lucidum, Codonopsis pilosula, Glycyrrhiza uralensis, Hedyotis diffusa, Pseudostellaria heterophylla, and Viola philippica. The present invention further provides a method for treating metastatic breast cancer in a subject in need thereof, comprising: administering to said subject an pharmaceutically effective amount of the composition.

Abstract: The present invention relates to a pharmaceutical composition and its preparation method for the eradication of Helicobacter pylorif in the forms of effervescent tablet, suspension or powder. The pharmaceutical composition comprises an effective dose of ?-lactam antibiotic, an effective dose of macrolide antibiotic, an effective dose of antacid such as proton pump inhibitor and H2 blocker, and a pharmaceutical acceptable carrier. An effective dose of alkaline substance such as carbonate or bicarbonate can be added to increase the pH of the stomach when the PPI antacid is used, which can protect the degradation of acid-labile antibiotics or PPI to further increase the bioavailability of the pharmaceutical composition for the purpose of Helicobacter pylori eradication.

Abstract: The invention provides a herbal composition for the inhibition of HIV, comprising an organic extract of Hedyotis diffusa (Oldenlandia diffusa), an organic solvent extract of Scutellaria barbata or Scutellaria rivularis, an organic solvent extract of Lonicera japonica or Lonicera confusato, an organic solvent extract of Prunella vulgari and an organi solvent extract of Solanum nigrum.

Abstract: The invention provides a herbal composition for the inhibition of HIV, comprising an organic extract of Hedyotis diffusa (Oldenlandia diffusa), an organic solvent extract of Prunella vulgaris and an organic solvent extract of Viola philippica (Viola yedoensis).

Abstract: The present invention relates to a new herbal composition for the prevention and/or treatment of the conditions in associated with depression. Also provided is a method of treating and/or preventing the conditions associated with depression by administering the herbal composition of the invention.

Abstract: An herbal extract of Euphorbia antiquorum is provided. The herbal extract of the invention demonstrates in vitro inhibition of growth of hepatoma cells, colorectal adenocarcinoma cells, monocyte-like lymphoma and leukemia cells. This invention also provides a pharmaceutical composition containing the same and a method for treatments for cancers.

Abstract: A method for fabricating the control gate and floating gate of a flash memory cell. An active area is firstly formed on a semiconductor substrate, followed by the formation of a first insulating layer, a first conductive layer and a first masking layer. A first opening is then formed by partially removing the first masking layer, and a floating gate oxide layer is formed by oxidation. The remaining first masking layer is removed, followed by forming a sacrificial layer, which is then partially removed to define a second opening. The remaining sacrificial layer is used as a hard mask to partially remove the first conductive layer and the first insulating layer to form a third opening. A second insulating layer is formed to fill the third opening to form an insulating plug. Part of the first conductive layer and the first insulating layer are removed to form a floating gate, followed by forming a third insulating layer and a second conductive layer.